Introduction
CCAAT/enhancer binding proteina (C/EBPa) was initially isolated from hepatocytes, and is also expressed in hematopoietic myeloid cells, adipocytes, and mammary, pulmonary, and small intestinal epithelia Birkenmeier et al., 1989; Scott et al., 1992; Chandrasekaran and Gordon, 1993; Antonson and Xanthopoulos, 1995) . C/EBPa dimerizes via its Cterminal leucine zipper (LZ) domain and binds DNA as an obligate dimer via the adjacent basic region . The 72 residue basic region-leucine zipper (bZIP) segment forms an extended a-helix in which the inner surface of the basic region contacts DNA (Vinson et al., 1989) . Once bound to DNA, C/ EBPa activates transcription via its N-terminal transactivation domains (Friedman et al., 1989; Friedman and McKnight, 1990; Nerlov and Ziff, 1994) .
The finding that C/EBPa is expressed at much higher levels in quiescent hepatocytes compared with proliferating hepatoma cells led to the initial suggestion that C/ EBPa contributes to terminal differentiation by inhibiting cell proliferation, as well as via gene activation (Friedman et al., 1989) . C/EBPa levels also increase during adipocyte maturation. Expression of C/EBPa-ER, in which C/EBPa has been rendered responsive to estradiol by fusion with the ligand-binding domain of the estradiol receptor (ER), slows the proliferation of 3T3-L1 preadipocytes without inducing differentiation in the absence of insulin and accelerates their differentiation in response to insulin (Umek et al., 1991) . Coexpression of HPV-16 E7, which increases free E2F by inactivating Rb, prevents C/EBPa from inhibiting proliferation in BALB/c fibroblasts, but does not interfere with induction of adipocytic of fat-specific genes (Muller et al., 1999) . In 32D cl3 myeloblasts, C/EBPa-ER induces granulocytic differentiation associated with G1 cell cycle arrest even in the absence of G-CSF, the physiologic inducer of granulopoiesis. C/EBPa-ER induces G1 arrest in these cells even if differentiation is inhibited via coexpression of Bcrabl(p210) (Wang et al., 1999) .
E2F is a key mediator of G1 progression. Mice lacking C/EBPa have increased expression of E2F-p107 complexes during hepatocyte development (Timchenko et al., 1999) , C/EBPa is detected in E2F DNA-binding complexes in fibroblasts and inhibits E2F-dependent transactivation (Slomiany et al., 2000) , and exogenous C/EBPa interacts with E2F in U937 myeloblasts (Johansen et al., 2001) . Inhibition of E2F-dependent transactivation and NIH3T3 cell proliferation is greatly reduced if C/EBPa residues 1-70 are deleted or if either Y285 or I294 and R297 are mutated to alanine. The latter three residues are located on the non-DNAbinding surface of the C/EBPa basic region and are required for interaction with E2F in hepatocytes (Porse et al., 2001) . Residues 1-70 may contribute a transrepression function. Cdk2 and Cdk4 also regulate the G1 to S transition. C/EBPa residues 177-191 are required for direct interaction with these proteins and for inhibition of COS7 cell proliferation (Wang et al., 2001) .
Mice harboring C/EBPa(BRM2), I294A and R297A, or C/EBPa(BRM5), Y285A, have a marked reduction in both white adipose tissue and mature, Gr-1+, granulocytic cells, but immature myeloid cells do not accumulate and liver development and function is normal (Porse et al., 2001) . In contrast, C/EBPa (À/À) mice lack adipocytes, have dysfunctional hepatocytes leading to neonatal hypoglycemia, and accumulate myeloblasts (Wang et al., 1995; Zhang et al., 1997) . Mutation of the outer surface of the basic region has a less severe effect than complete lack of C/EBPa, allowing lineage commitment but perhaps accelerating apoptosis of mature granulocytes via excessive E2F activity (Porse et al., 2001) .
Analysis of 32D cl3 cells expressing C/EBPa-ER or of C/EBPaBRM2 or C/EBPaBRM5 knockin mice has not resolved whether cell cycle inhibition by C/EBPa is required for differentiation in granulocytes. In this study, we have employed regulated expression of a panel of C/EBPa-ER variants to determine whether inhibition of G1 progression by C/EBPa is necessary or sufficient for its ability to induce granulopoiesis. We gained additional insight by assessing the effects of mimosine, an agent that increases the expression of the p27 cyclin-dependent kinase inhibitor. C/EBPa was first shown to induce granulocytic differentiation in human myeloid leukemia cell lines (Radomska et al., 1998) . We employed 32D cl3 cells for this study as they are diploid, nonleukemic, and IL-3 dependent for survival and proliferation, properties that suggest they harbor fewer potentially confounding mutations. Our findings indicate that cell cycle arrest mediated by the outer surface of the C/EBPa basic region is necessary but not sufficient for granulopoiesis.
Results
Cell cycle inhibition by C/EBPa is not sufficient for granulopoiesis C/EBPaL12V carries point mutants which convert the first two leucines of the C/EBPa LZ to valine, and C/ EBPaBR3 carries mutations in residues within the C/ EBPa basic region (Figure 1a ). These C/EBPa variants do not bind DNA or activate transcription (Friedman et al., 1989) . To evaluate their effect on proliferation and differentiation, 32D cl3 cells were transduced with the pBabePuro-C/EBPaL12V-ER and pBabePuro-C/EBPaBR3-ER retroviral vectors. Expression of these C/ EBPa variants in 32D cl3 subclones obtained by limiting dilution was similar to the level of wild-type (WT) C/EBPaER present in a previously characterized cell line (Wang et al., 1999; Figure 1b) .
Activation of C/EBPa-ER with estradiol markedly slows G1 to S cell cycle progression in 32D cl3 cells proliferating in IL-3 (Wang et al., 1999) . 32D-C/EBPa-ER, 32D-C/EBPaL12V-ER, 32D-C/EBPaBR3-ER were cultured in the presence of estradiol or the ethanol vehicle. 32D-ER cells, expressing the ER segment alone (Wang and Friedman, 2002) , were cultured similarly. After 48 h, cells were subject to propidium iodide (PI) staining and fluorescent-activated cell sorter (FACS) analysis to determine the proportion of cells in each cell cycle phase and the degree of apoptosis, represented by cells with sub-2n DNA content. A representative experiment is shown in the top panels of Figure 2a , and quantitative analysis of the effect of estradiol on the G1/S ratio is shown in Figure 2b . An increased G1/S Figure 1 Expression of C/EBPa-ER and mutant variants that cannot bind DNA. (a) Diagram of C/EBPa-ER (aER), the ER segment alone, and the L12 V, BR3, GZ, BRM2, D1-2, and D1-2,7 C/EBPa-ER mutant variants. In L12 V, the first two leucines of the LZ are changed to valines. In BR3, four residues in the basic region are altered, including one that contacts DNA. In GZ, the GCN4 LZ replaces the C/EBPa LZ. BRM2 carries mutations in two residues in the outer surface of the C/EBPa basic region, one of which is also mutant in BR3. D1-2 lacks residues 11-70, and D1-2,7 lacks these residues and amino acids 178-200. Regions that interact with E2F directly (selected residues in the outer surface of the BR), which contribute to repression of E2F targets (residues 11-70), and which bind cdk2/4 are also indicated. (b) Western blot of 1 Â 10 6 parental 32D cl3 cells (À) or cell lines stably expressing aER, L12 V, or BR3. The blot was probed sequentially using an ER antiserum and b-actin antibody ratio reflects inhibition of G1 to S cell cycle progression. C/EBPa-ER potently slowed G1 progression, as described previously for this subclone and a second subclone (Wang et al., 1999) , C/EBPaBR3-ER also was strongly inhibitory to a similar extent in both subclones, C/EBPaL12V-ER had a more modest effect, and ER was ineffective.
To determine whether cell cycle inhibition by the L12V or BR3 variants was sufficient to mediate granulocytic differentiation, RNA samples prepared from these lines cultured in the presence of estradiol were subjected to Northern blotting for myeloperoxidase (MPO) and lysozyme (Lys) (Figure 3a ). C/EBPa-ER induced MPO by day 1 and Lys by day 3, whereas these RNAs were not induced in two L12V and in two BR3 subclones. Basal expression of Lys in IL-3, as seen in the BR3 cells, has been observed in other 32D cl3 subclones (Wang and Friedman, 2002) . In addition, examination of cell cytospins indicated that neither C/ EBPaL12V nor C/EBPaBR3 induced morphologic differentiation ( Figure 3b and data not shown). Thus, cell cycle inhibition mediated by C/EBPa is not sufficient to induce granulopoiesis, whereas interaction of C/EBPa with its genetic targets is required.
Cell cycle inhibition via the C/EBPa basic region is required for granulopoiesis
Several domains of C/EBPa participate in its inhibition of G1 to S cell cycle progression in nonmyeloid cells. To determine their role in 32D cl3 cells, we developed retroviral vectors expressing C/EBPaD1-2-ER, lacking the N-terminal domain required for repression of E2F targets, C/EBPaD1-2,7-ER, also lacking the cdk2/cdk4-interaction domain, and C/EBPaBRM2-ER, carrying mutations in residues in the outer surface of the basic region required for interaction with E2F (Porse et al., 2001; Wang et al., 2001) . Deletion of regions 1 and 2 does not affect C/EBPa transactivation, whereas region 7 is part of TAD2 (Friedman and McKnight, 1990 ). In addition, we developed a vector expressing C/EBPaGZ, in which the C/EBPa LZ has been replaced with the GCN4 LZ. C/EBPaGZ retains the ability to dimerize and activate C/EBPa target genes (Friedman and The G1/S ratio obtained for each indicated cell line after exposure to estradiol for 2 days was divided by the G1/S ratio observed in untreated cells. A higher G1/S ratio indicates greater inhibition of G1 to S progression (mean and s.e. from two determinations) McKnight, 1990) . Substitution of the GCN4 LZ tests the idea that heterodimerization of C/EBPa with proliferative bZIP proteins, such as c-Jun (Hsu et al., 1994) , mediates cell cycle inhibition in myeloid cells. These four C/EBPa-ER variants are diagrammed in Figure 1a . A Western blot comparing expression in 32D cl3 subclones of these variants and the ER segment with C/EBPa-ER is presented in Figure 4 . Each C/EBP fusion is expressed at comparable levels, although expression in D1-2,7 and BRM2-1 cells is reduced compared to the other lines. Despite screening multiple 32D cl3 subclones, we did not identify one expressing similar levels of the ER segment alone (Wang and Friedman, 2002) .
The effect of each C/EBPa-ER variant on cell cycle progression was assessed (Figure 2b ). C/EBPaGZ-ER, C/EBPaD1-2-ER, and C/EBPaD1-2,7-ER each slowed G1 progression, albeit not as effectively as C/EBPa-ER, whereas C/EBPaBRM2-ER was ineffective in both BRM2-1 and BRM2-2 cells. Although several C/EBPa domains contributed to its ability to slow G1 progression, the outer surface of the basic region was most critical. Assessment of cell cycle inhibition after 2 days was problematic because of excessive apoptosis in cell lines in which G1 progression was slowed. However, BRM2-1 and BRM2-2 cells did not exhibit G1/S cell cycle arrest even at day 4, although apoptosis was evident in approximately 20% of the cells (not shown). The proliferation of BRM2-2 cells in the presence or absence of estradiol is compared to ER, aER, D1-2, D1-2,7, and GZ-1 cells (Figure 5a ). In contrast to early onset of cell death evident in 32D cl3 lines expressing these four variants, 32D cl3 proliferation was only minimally slowed by C/EBPaBRM2 for the first 5 days Figure 3 Cell cycle arrest mediated by C/EBPa is not sufficient for granulocytic differentiation. (a) Total cellular RNAs were prepared from 32D-C/EBPa-ER cells (aER) or from two C/EBPaL12V-ER (L12V-1, L12V-2), and from two C/EBPaBR3-ER (BR3-1, BR3-2) subclones exposed to estradiol for 0, 1, or 3 days, in IL-3. These RNAs, 10 mg per sample, were subjected to Northern blotting for MPO, Lys, and b-actin. (b) aER, L12V-1, and BR3-1 cells exposed to estradiol for 0 or 3 days were cytospun and subjected to Wright's-Giemsa staining ( Â 60 magnification) after estradiol addition. Similar results were obtained with BRM2-1 cells (not shown). Late onset cell death was evident in the BRM2 lines.
As terminal granulocytic differentiation is linked to cell cycle arrest, we expected from these findings that C/ EBPaBRM2 cells were not maturing at the same rate as aER cells when exposed to estradiol. To determine whether cell cycle inhibition by C/EBPa-ER is required for induction of granulocytic differentiation, we subjected RNA samples prepared from 32D-C/EBPaBRM2-ER-1 cells cultured in estradiol to Northern blotting ( Figure 5b ). MPO is a marker of early stage, Lys and C/EBPe of intermediate stage, and lactoferrin (LF) of late stage granulopoiesis. Compared to 32D-C/ EBPa-ER cells, MPO and Lys induction were reduced, and LF induction was minimal. Reduced actin expression in the day 3 aER sample is because of the ongoing apoptosis. MPO, Lys, and LF RNAs were also poorly induced in BRM2-2 cells in estradiol (not shown). C/ EBPe mRNA was induced to control levels in BRM2-1 cells, but this was not sufficient to induce LF mRNA or a G1 arrest. Consistent with the Northern blot results, BRM2-2 cells did not develop a neutrophilic morphology when exposed to estradiol for 7 days (Figure 5c ), and BRM2-1 cells behaved similarly (not shown).
Mutation of the outer surface of the C/EBPa basic region is not expected to affect DNA binding or transactivation. In fact, C/EBPa and C/EBPaBRM2 knockin mice display similar levels of C/EBPa protein and DNA-binding activity in liver nuclear extracts (Porse et al., 2001) . To quantitatively compare the ability of the C/EBPs to bind DNA, we prepared gel shift extracts from 293 T cells transduced with their expression vectors for C/EBPa-ER or C/EBPaBRM2-ER and exposed to estradiol. These extracts were subjected to gel shift assay using a range of unlabelled WT and mutant (MUT) oligonucleotide competitors (Figure 6a ). Binding by both C/EBPs was inhibited similarly by three-or 10-fold excess WT competitor and was not affected by the MUT competitor. To compare transactivation by C/EBPa-ER and C/EBPaBRM2-ER, their expression vectors were cotransfected with p(C/ EBP) 2 TKLUC into duplicate wells of 293 T cells, which were then exposed to estradiol or the ethanol vehicle
Figure 4 Expression of C/EBPa-ER and variants mutant in domains potentially required for cell cycle inhibition. Western blot of 1 Â 10 6 parental 32D cl3 cells (À) or subclones stably expressing aER, GZ, D1-2,7, D1-2, or BRM2. The blot was probed using ER antiserum (top panel). The protein content of each sample was assessed by staining a replicate gel with Coomassie blue (bottom panel) Figure 5 Cell cycle inhibition by C/EBPa is required for terminal granulopoiesis. (a) The indicated cell lines were seeded at 3 Â 10 4 cells/ml in the absence or presence of estradiol, and viable cell counts were obtained on days 1-4. (b) aER and BRM2-1 cells were exposed to estradiol for 0, 1, or 3 days, in IL-3. These RNAs were subjected to Northern blotting for MPO, Lys, C/EBPe, LF, and b-actin. (c) BRM2-2 cells exposed to estradiol for 0, 4, or 7 days were cytospun and subjected to Wright's-Giemsa staining ( Â 60 magnification) (Figure 6b ). Each potently activated transcription, 40-versus 28-fold. In addition, C/EBPa and C/ EBPaBRM2 each activated the reporter 30-fold. Also, C/EBPaGZ-ER activated the reporter 27-fold, C/EBPaD1-2-ER 20-fold, and C/EBPaD1-2,7-ER 13-fold (not shown).
G1 cell cycle arrest inhibits early and accelerates late granulopoiesis
Having demonstrated that cell cycle arrest contributes to early granulopoiesis and is required for terminal maturation, we sought to gain additional insight into the contribution cell cycle arrest makes to the expression of granulocytic markers by inhibiting G1 progression, while allowing induction of endogenous C/ EBPa and granulopoiesis by G-CSF. Mimosine is a novel amino acid which elevates the level of the p27 Kip1 cdk inhibitor (Wang et al., 2000) , inactivating cdk2 and so preventing release of E2F from Rb family members. Induction of p27 by mimosine in 32D cl3 cells in IL-3 or G-CSF is shown in Figure 7a . We examined the effect of mimosine in 32D-KaER/GR cells (Wang and Friedman, 2002) , which express both a dominant-inhibitory C/ EBP, KaER, and exogenous G-CSFR receptor. In this way, the effects of mimosine in G-CSF could be assessed independent of potentially confounding affects on G-CSF receptor levels, and the effects of mimosine could be compared with KaER, which inhibits C/EBPregulated genes. Differentiation induced by G-CSF slows G1 progression (Figure 7b , top panels). Exposure to mimosine for 1 day, beginning at either 0 or 72 h, further slows G1 (Figure 7b, bottom) , to an extent similar to that obtained with activation of C/EBPa-ER in IL-3 (Figure 2a ). Owing to cell death, mimosine exposure could not be continued beyond 3 days. Activation of KaER with 4-hydroxytamoxifen (4HT) mildly slows G1 (Figure 7b, bottom) . Mimosine reduced MPO but elevated Lys RNA expression, in cell proliferating in IL-3, just transferred to G-CSF, or transfered to G-CSF 3 days earlier, whereas 4HT reduced both RNAs (Figure 7c, d) . The specific effect of mimosine on MPO may reflect maximal expression of MPO RNA at a more immature, proliferative stage of granulopoiesis, compared with Lys RNA. Mimosine and KaER also reduced c-Myb RNA levels (Figure 7c ). c-Myb stimulates proliferation and directly activates MPO gene expression (Britos-Bray and Friedman, 1997) ; its reduced expression may be a consequence of slowed G1 progression and could account for the effect of mimosine on MPO RNA levels.
When added to cells transferred to G-CSF 3 days earlier, mimosine increased both Lys and LF RNA expression, but did not affect C/EBPb or C/EBPe RNA levels (Figure 7c ). If mimosine and 4HT were added simultaneously after 3 days, Lys expression was reduced to that seen in IL-3 (not shown). Increased Lys and LF RNA expression, intermediate and late markers of granulopoiesis, suggests that cell cycle arrest stimulates the later stages of granulocytic differentiation. On the other hand, inhibition of Lys and LF RNA expression by KaER despite the presence of KaER and/or mimosine-induced G1 arrest indicates that transactivation by C/EBPs is required as well for their expression.
Discussion
Despite the finding that C/EBPa both activates lineagespecific genes and slows G1 progression, the specific contribution of cell cycle arrest mediated by C/EBPa to granulopoiesis or to maturation of other lineages has not been resolved. Using a panel of C/EBPa mutants we have separated its ability to activate its genetic targets and to slow G1, progression. C/EBPaL12V-ER and C/ EBPaBR3-ER retain the ability to slow G1, but do not induce markers of differentiation. One caveat to these results is that cell cycle arrest by these variants is not as potent as that obtained with C/EBPa-ER. However, (G1, G2, G3 ), G-CSF for 1 day with 4HT or mimosine (G1, 4HT1, and G1, mim1), or G-CSF for 4 days with 4HT or mimosine added on day 3 (G4, 4HT1, and G1, mim1) were subjected to PI staining and FACS analysis. (c, d) RNAs prepared from 32D-KaER/GR cells cultured in the indicated conditions were subjected to Northern blotting for MPO, Lys, c-Myb, LF, C/EBPb, C/EBPe, and b-actin as indicated. +1, +2, and +3 indicate the number of days 4HT or mimosine was present just prior to RNA preparation mimosine arrests G1 progression as potently as C/ EBPa-ER, via a pathway expected to reduce free E2F levels, and prevents MPO RNA expression. Together these findings indicate that cell cycle inhibition, by C/ EBPa or by other means, is not sufficient to induce granulopoiesis. In addition, we previously demonstrated that KaER, which both slows G1 progression and transrepresses C/EBP-regulated genes, prevents all stages of granulopoiesis, indicating that activation of C/EBP-regulated genes is required.
We also sought to identify a C/EBPa-ER variant that does not slow G1 to S cell cycle progression, but retains the ability to bind DNA and activate transcription. After examining the effect of several candidates, based upon known interaction domains for E2F, cdk2, cdk4, and c-Jun, we found that mutation of the outer surface of the C/EBPa-ER basic region had the most profound effect in 32D cl3 myeloid cells. 32D-C/EBPaBRM2 cells did not arrest in G1 when exposed to estradiol, even though they retain regions 1-2 and 7. Future experiments will identify the precise basic region residues required for inhibition of G1 progression in 32D cl3 cells and will determine whether these are also required for interaction with E2F, or potentially with other proteins.
Activation of C/EBPaBRM2-ER did not lead to terminal differentiation, whereas C/EBPa-ER induced the formation of neutrophils over a 3 day period. Induction of MPO and Lys by C/EBPaBRM2-ER was also reduced, relative to C/EBPa-ER, suggesting that reduced proliferation rate is also required for optimal expression of these earlier markers. Late onset of apoptosis was seen in BRM2 lines, consistent with the postulate that the lack of mature granulocytes in BRM2 knockin mice results from apoptosis mediated be excessive E2F activity (Porse et al., 2001) . Perhaps, late apoptosis depends upon the protein products of genes activated by C/EBPaBRM2 at early times. C/EBPa and C/EBPaBRM2 bound DNA and activated transcription equivalently, suggesting that differences in their ability to regulate endogenous genes does not account for their different effects on granulopoiesis, but it remains possible that C/EBPa cooperates with another transcription factor via the outer surface of its basic region on a subset of target genes. C/EBPaGZ-ER induced 32D cl3 cells to differentiate to mature neutrophils, whereas C/EBPaD1-2 and C/EBPaD1-2,7 did not (data not shown). The consequences of these mutations for C/ EBPa functions will be investigated further in the future. The finding that C/EBPaD1-2 slows G1 progression suggests that the 30 Kda C/EBPa isoform expressed from an internal ATG in a subset of acute myeloid leukemia cases (Pabst et al., 2001) would act similarly, necessitating additional mutations that accelerate G1 for transformation.
Results obtained with mimosine indicate that cell cycle arrest mediated by C/EBPa contributes to the latter stages of granulopoiesis by facilitating activation of lineage-specific genes, including those encoding Lys and LF. Similarly, transient expression of p21 or p27 in U937 cells induced monocytic markers, CD11b and CD14 (Liu et al., 1996) . The mechanism underlying these effects is unknown, although an increase in hypophosphorylated Rb family members could contribute to maturation via interaction with PU.1 or C/EBPb (Hagemeier et al., 1993; Chen et al., 1996) . We have been unable to generate 32D cl3 lines in which C/EBPa-ER-mediated growth inhibition is prevented because of the coexpression of E7, cdk4, or cyclin D2, proteins, which stimulate G1 progression. In any case, assessment of C/EBP-induced differentiation in such lines would be complicated by the finding that cdk4, cyclin D2, or E2F1 prevent the latter stages of granulopoiesis (Kato and Sherr, 1993; Strom et al., 1998; Lou et al., 2000) .
Terminal differentiation is invariably associated with cell cycle arrest, and expression or downregulation of transcriptional regulators such as MyoD, c-Myb, AML1/Runx1, and C/EBPa may link early differentiation with proliferation and terminal differentiation with cell cycle arrest (Friedman, 2002a, b) . In muscle cells, MyoD, like C/EBPa, both inhibits proliferation and induces lineage-specific genes (Crescenzi et al., 1990) . et al., 1995) . We have now found that cell cycle arrest lowers c-Myb levels, indicating a feedback mechanism to ensure unidirectional maturation. AML1/Runx1 also activates genes in immature myeloid cells and stimulates their proliferation (Lou et al., 2000) , and AML1/Runx1 levels are lower in G1 than in S or G2/M in 32D cl3 cells (F Bernardin and ADF, unpublished) . We have postulated that the proliferative effects of c-Myb and CBF/Runx1 dominate the antiproliferative effect of C/EBPa in immature granulocytes, but that C/EBPa acts unopposed once the cells reach the myelocyte stage (Friedman, 2002b) . In summary, cell cycle arrest is necessary for terminal granulopoiesis, and C/EBPa is capable of directing the requisite G1 inhibition by interacting with E2F via the outer surface of its basic region, and not indirectly via gene activation. C/EBPa sets in motion a full program of granulocytic differentiation. Gene activation by C/ EBPaBRM2 is not sufficient to induce a program leading to cell cycle arrest or terminal granulopoiesis. Our findings support a model in which C/EBPa plays a central role in the cell cycle arrest required for normal granulopoiesis.
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Materials and methods
Cell culture, transduction, and cell cycle analysis 32D cl3 cells (Valtieri et al., 1987) were maintained in phenol red-free Iscoves modified Dulbecco medium (IMDM) with 10% heat-inactivated fetal calf serum (HI-FCS), 1 ng/ml IL-3 (PeproTech, Rocky Hill, NJ, USA), and penicillin (100 units/ ml) and streptomycin (100 mg/ml). 32D cl3 were washed twice with phosphate-buffered saline before transfer to IMDM with 10% HI-FCS and 20 ng/ml G-CSF (Amgen, Palo Alto, CA, USA). jCRE cells (Danos and Mulligan, 1988) were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% HI-FCS. 293 T cells were cultured in DMEM with 10% HI-FCS. Retroviral vectors were introduced into jCRE cells using Lipofectamine 2000 (Gibco-BRL, Gaithersburg, MD, USA), and pooled transfectants were selected using 2 mg/ml puromycin. 32D cl3 cells were transduced by coculture with subconfluent jCRE packaging cells irradiated to 3000 cGy and 4 mg/ml Polybrene. Subclones were isolated by limiting dilution in 2 mg/ml puromycin. We employed 1 mm estradiol (E2) or 200 nm 4HT to activate ER fusion proteins and 0.1% ethanol as a vehicle control. Mimosine (Sigma, St Louis, MO, USA) was employed at 100-200 mm from a 100 mm stock in 0.1 n NaOH. Morphology was assessed by Wright's-Giemsa staining of cytospins. Viable cell counts were obtained by enumerating, by means of a hemocytometer, cells that exclude trypan blue dye. The proportion of cells in each cell cycle phase was determined by FACS analysis of cells stained with PI as described (Cao et al., 1997) .
Plasmids and transient transfection
pBabePuro-C/EBPaL12V-ER, -C/EBPaBR3-ER, and -C/EBPaD1-2-ER, were constructed by replacing a 1.1 kb NcoI fragment containing the majority of the C/EBPa open-reading frame with the analogous NcoI fragment from pMSV-C/ EBPaBR3, -C/EBPaL12 V, or -C/EBPaD1-2 (Friedman et al., 1989; Friedman and McKnight, 1990) . pBabePuro-C/EBPaD1-2,7-ER was constructing by inserting a NotI/SstI fragment from pMSV-C/EBPD7 into pBabePuro-C/EBPaD1-2-ER. pBabePuro-C/EBPaGZ-ER was constructed by transfering the C/EBPaGZ cDNA from pMSV-C/EBPaGZ (Friedman and McKnight, 1990 ) to pBabePuro and then linking the human ER ligand-binding domain in frame with the C-terminus of the GCN4 leucine zipper (GZ) after inserting a restriction site just upstream of the GCN4 stop codon by PCR mutagenesis. As a result, the final GCN4 residue, Arg, was lost, and Ala-Lys-Pro-Asn-Leu was inserted between the GCN4 and ER segments, as confirmed by DNA sequencing. p(C/EBP) 2 TKLUC and pCMV-bGAL were described (Wang and Friedman, 2002) . For luciferase assays, 293T cells seeded the day before at 8 Â 10 4 cells per well in six-well dishes were transfected with 800 ng plasmid DNA and 3 ml Lipofectamine, 2000. Luciferase and b-galactosidase assays were carried out 2 days later as described (Oelgeschla¨ger et al., 1996) . For preparing gel shift extracts, 5 mg of plasmid DNA was transfected with 20 ml Lipofectamine per 100 mm dish.
Western and Northern blotting and gel shift assay
Preparation of total cellular protein and RNA and Western and Northern blotting were carried out as described (Wang and Friedman, 2002) . We employed ERa (HC-20) antiserum (Santa Cruz Biotech., Santa Cruz, CA, USA), actin antibody AC-15 (Sigma, St Louis, MO, USA), and p27
Kip1 antibody 13231A (Pharmingen, San Diego, CA, USA). Protein gels were stained with 0.25% (w/v) Coomassie blue in 50% (v/v) methanol/10% (v/v) acetic acid for 4 h and destained in 50% methanol/10% acetic acid. The MPO, Lys, LF, C/EBPb, C/ EBPe, c-Myb, and b-actin cDNAs employed as probes have been described (Oelgeschla¨ger et al., 1996; Wang and Friedman, 2002) . The sense strands of the oligonucleotides employed for gel shift assays were: C/EBP(NE): 5 0 -TCGAGGCCAGGATGGGGCAATACAACCCG-3 0 and mC/EBP(NE): 5 0 -TCGAGGCCAGGACTCGAGGATA-CAACCCG-3 0 . The antisense oligonucleotides had corresponding GATC or TCGA 5 0 overhangs. The WT and MUT C/EBP binding sites are underlined. Preparation of 293 T nuclear extracts and gel shift assays were carried out as described (Oelgeschla¨ger et al., 1996) .
